- Home
- AEF vs ALT Comparison
AEF vs ALT Comparison
Compare AEF & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AEF | ALT |
|---|---|---|
| Founded | 1989 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 351.6M | 415.3M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | AEF | ALT |
|---|---|---|
| Price | $8.73 | $4.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 167.9K | ★ 3.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.13% | N/A |
| EPS Growth | N/A | ★ 19.28 |
| EPS | ★ 0.57 | N/A |
| Revenue | N/A | ★ $20,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.60 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.43 | $2.91 |
| 52 Week High | $8.93 | $7.73 |
Technical Indicators
Market Signals| Indicator | AEF | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 70.98 | 44.18 |
| Support Level | $6.31 | $3.78 |
| Resistance Level | N/A | $4.53 |
| Average True Range (ATR) | 0.15 | 0.21 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 80.81 | 23.93 |
Price Performance
Historical ComparisonAbout AEF abrdn Emerging Markets Equity Income Fund Inc.
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, private equity, communication services, healthcare, real estate, and industrials.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.